Fox Run Management L.L.C. acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 4,666 shares of the biopharmaceutical company’s stock, valued at approximately $360,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp grew its holdings in Gilead Sciences by 11.6% during the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock valued at $2,191,575,000 after purchasing an additional 3,221,439 shares during the period. Northern Trust Corp grew its holdings in Gilead Sciences by 2.0% during the second quarter. Northern Trust Corp now owns 16,823,192 shares of the biopharmaceutical company’s stock valued at $1,191,754,000 after purchasing an additional 325,246 shares during the period. Sanders Capital LLC grew its holdings in Gilead Sciences by 7.0% during the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock valued at $804,126,000 after purchasing an additional 696,200 shares during the period. Boston Partners grew its holdings in Gilead Sciences by 3.1% during the second quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock valued at $587,300,000 after purchasing an additional 245,805 shares during the period. Finally, OppenheimerFunds Inc. grew its holdings in Gilead Sciences by 0.3% during the second quarter. OppenheimerFunds Inc. now owns 7,038,387 shares of the biopharmaceutical company’s stock valued at $498,599,000 after purchasing an additional 22,916 shares during the period. 77.99% of the stock is owned by institutional investors.

In other news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 150,000 shares of company stock worth $11,502,500 over the last 90 days. Company insiders own 1.16% of the company’s stock.

Several analysts have issued reports on GILD shares. BidaskClub lowered Gilead Sciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 20th. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, June 27th. Raymond James started coverage on Gilead Sciences in a report on Thursday, June 28th. They set a “strong-buy” rating and a $93.00 price target for the company. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Wednesday, July 18th. Finally, Robert W. Baird lowered Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a report on Thursday, July 26th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $88.24.

Shares of Gilead Sciences stock opened at $74.78 on Thursday. Gilead Sciences, Inc. has a 52 week low of $64.27 and a 52 week high of $89.54. The stock has a market capitalization of $100.09 billion, a PE ratio of 8.74, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The business had revenue of $5.65 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the previous year, the business earned $2.56 earnings per share. The business’s revenue was down 20.9% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 27th. Stockholders of record on Friday, September 14th were given a $0.57 dividend. The ex-dividend date was Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.05%. Gilead Sciences’s payout ratio is 26.64%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.